Seprase (FAP)-Targeted Imaging Agent Development
At Alfa Cytology, we are specializing in modern imaging agent development services effective against the seprase (FAP). Through its expert team and up-to-date facilities, it is able to offer a wide range of comprehensive solutions towards the upliftment of your drug development. We envision incorporating true excellence and innovation in the field of seprase (FAP)-targeted therapies wherein you can trust us as partners.
Introduction to Seprase (FAP)-Targeted Imaging
Seprase (FAP) could behave ideally as a target for tumor imaging since it is extensively overexpressed in cancer-associated fibroblasts found in the tumor microenvironment. The seprase (FAP)-targeted imaging agents could allow for a more accurate means for viewing tumor mass and help with early diagnosis, treatment planning, and monitor therapeutic efficacy.
Fig. 1 Superiority of FAPI PET over FDG PET in Gastrointestinal cancers. (Arçay Öztürk, A., et al. 2023)
Development of Seprase (FAP)-Targeted Imaging Agent
The following are seprase (FAP)-targeted imaging tracer, including but not limited to:
| Name | Type | Imaging Modality | Phase |
|---|---|---|---|
| Seprase (FAP)-Targeted Nanobody | Radiolabeled Single Domain Antibodiy | SPECT or PET | Preclinical |
| [18F] AlF-NOTA-FAPI | Radiolabeled Small Molecule Seprase (FAP) Inhibitor | PET | Preclinical |
| Seprase (FAP)-Targeted Antibody-Based Tracer | Radiolabeled Monoclonal Antibody | PET | Preclinical |
| 99mTc-FAPI | Radiolabeled Small Molecule Seprase (FAP) Inhibitor | SPECT | Preclinical |
| [64Cu] Cu-FAPI-04 | Radiolabeled Small Molecule Seprase (FAP) Inhibitor | PET | Early Clinical Trial |
| [18F] FAPI-74 | Radiolabeled Small Molecule Seprase (FAP) Inhibitor | PET | Phase I/II |
| [68Ga] Ga-FAPI-04 | Radiolabeled Small Molecule Seprase (FAP) Inhibitor | PET | Phase II |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Alfa Cytology is a single solution provider for your seprase (FAP)-targeted imaging development path from concept to product. Our services include:
Development and Evaluation of Seprase (FAP)-Targeted Imaging Agent
Radiolabeled Small Molecule Seprase (FAP) Inhibitors- Development and optimization of radiolabeled seprase (FAP) inhibitors suitable for PET or SPECT imaging.
- Synthesis of novel radiotracers characterized by enhanced stability and targeting-specificity.
Antibody or Peptide-Based Imaging Agents- Creation of seprase (FAP)-targeted monoclonal antibodies, nanobodies, or peptides labeled with radionuclides or fluorescent dyes for high-specificity imaging applications.
- Customization of imaging agents to improve pharmacokinetics and biodistribution profiles.
Preclinical Research of Seprase (FAP)-Targeted Imaging Agent
In Vitro Assays- Cell-based assays for evaluation of seprase (FAP) expression levels and binding specificity of imaging agents.
- Determining the stability and activity of imaging agents in biological systems.
In Vivo Animal Imaging- Develop xenograft mouse models that express high levels of seprase (FAP) for in vivo imaging studies.
- Provide through advanced imaging modalities, assessment of biodistribution, pharmacokinetics, and targeting efficacy of the imaging agents.
Customized Synthesis and Tailored Services
Isotope Labeling Customization
- Provision of radiolabeling with various isotopes such as 68Ga, 18F, and 64Cu suiting various imaging as well as half-life optimization requirements.
- Optimization of labeling protocols to maximize radiochemical yield and purity.
Compound Modification and Optimization
- Structural modification of imaging agents to enhance pharmacokinetic properties and targeting specificity based on client specifications.
- Analytical support including purity assessment, stability testing, and activity verification.
Accelerate your seprase (FAP)-targeted imaging projects, Delivered by Alfa Cytology. With expertise and comprehensive services, your development process becomes more streamlined, thus affording high-quality outcomes. Get in touch today with us to explore how we can boost your research and advance the therapeutic objectives.
Reference
- Arçay Öztürk, A., et al. Seprase (FAP)-Targeted PET imaging in gastrointestinal malignancies: a comprehensive review. Cancer imaging: the official publication of the International Cancer Imaging Society. 2023, 23(1): 79.
For research use only.